How much profit has MedMira made this year?
MedMira has made -2.68 M CAD this year.
MedMira Net Income 2024
MedMira Net Income
-2.68 M CAD
Ticker
MIR.V
ISIN
CA58501R1029
WKN
932414
In 2024, MedMira's profit amounted to -2.68 M CAD, a 46.08% increase from the -1.83 M CAD profit recorded in the previous year.
The MedMira Net Income history
| YEAR | NET INCOME (undefined CAD) |
|---|---|
| 2023 | -2.68 |
| 2022 | -1.83 |
| 2021 | -0.68 |
| 2020 | -2.05 |
| 2019 | -2.11 |
| 2018 | -2.51 |
| 2017 | -2.66 |
| 2016 | -5.16 |
| 2015 | -3.5 |
| 2014 | -3.84 |
| 2013 | -0.4 |
| 2012 | 3.37 |
| 2011 | -4.93 |
| 2010 | -4.42 |
| 2009 | -5.26 |
| 2008 | -7.02 |
| 2007 | -6.29 |
| 2006 | -7.29 |
| 2005 | -5.9 |
| 2004 | -3.99 |
MedMira Revenue, EBIT, Net Income CA58501R1029 · 932414
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into MedMira, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MedMira from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MedMira’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of MedMira. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into MedMira’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing MedMira’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MedMira’s growth potential.
MedMira Revenue, EBIT and net profit per share
| Date | MedMira Revenue | MedMira EBIT | MedMira Net Income |
|---|---|---|---|
| 2023 | 432,530 undefined | -1.94 M undefined | -2.68 M undefined |
| 2022 | 952,130 undefined | -1.45 M undefined | -1.83 M undefined |
| 2021 | 2.14 M undefined | -184,230 undefined | -675,800 undefined |
| 2020 | 919,070 undefined | -1.3 M undefined | -2.05 M undefined |
| 2019 | 527,450 undefined | -1.3 M undefined | -2.11 M undefined |
| 2018 | 588,870 undefined | -1.84 M undefined | -2.51 M undefined |
| 2017 | 747,340 undefined | -2.13 M undefined | -2.66 M undefined |
| 2016 | 2.26 M undefined | -4.48 M undefined | -5.16 M undefined |
| 2015 | 4.05 M undefined | -2.74 M undefined | -3.5 M undefined |
| 2014 | 2.53 M undefined | -3.57 M undefined | -3.84 M undefined |
| 2013 | 2 M undefined | -2.17 M undefined | -400,000 undefined |
| 2012 | 970,000 undefined | -2.16 M undefined | 3.37 M undefined |
| 2011 | 910,000 undefined | -1.86 M undefined | -4.93 M undefined |
| 2010 | 1.07 M undefined | -2.29 M undefined | -4.42 M undefined |
| 2009 | 1.14 M undefined | -2.51 M undefined | -5.26 M undefined |
| 2008 | 1.53 M undefined | -3.22 M undefined | -7.02 M undefined |
| 2007 | 1.71 M undefined | -3.55 M undefined | -6.29 M undefined |
| 2006 | 2.09 M undefined | -5.48 M undefined | -7.29 M undefined |
| 2005 | 2.66 M undefined | -4.45 M undefined | -5.9 M undefined |
| 2004 | 2.48 M undefined | -3.45 M undefined | -3.99 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 2.48 M CAD | -3.45 M CAD | -3.99 M CAD |
| 2005 | 2.66 M CAD | -4.45 M CAD | -5.9 M CAD |
| 2006 | 2.09 M CAD | -5.48 M CAD | -7.29 M CAD |
| 2007 | 1.71 M CAD | -3.55 M CAD | -6.29 M CAD |
| 2008 | 1.53 M CAD | -3.22 M CAD | -7.02 M CAD |
| 2009 | 1.14 M CAD | -2.51 M CAD | -5.26 M CAD |
| 2010 | 1.07 M CAD | -2.29 M CAD | -4.42 M CAD |
| 2011 | 910,000 CAD | -1.86 M CAD | -4.93 M CAD |
| 2012 | 970,000 CAD | -2.16 M CAD | 3.37 M CAD |
| 2013 | 2 M CAD | -2.17 M CAD | -400,000 CAD |
| 2014 | 2.53 M CAD | -3.57 M CAD | -3.84 M CAD |
| 2015 | 4.05 M CAD | -2.74 M CAD | -3.5 M CAD |
| 2016 | 2.26 M CAD | -4.48 M CAD | -5.16 M CAD |
| 2017 | 747,340 CAD | -2.13 M CAD | -2.66 M CAD |
| 2018 | 588,870 CAD | -1.84 M CAD | -2.51 M CAD |
| 2019 | 527,450 CAD | -1.3 M CAD | -2.11 M CAD |
| 2020 | 919,070 CAD | -1.3 M CAD | -2.05 M CAD |
| 2021 | 2.14 M CAD | -184,230 CAD | -675,800 CAD |
| 2022 | 952,130 CAD | -1.45 M CAD | -1.83 M CAD |
| 2023 | 432,530 CAD | -1.94 M CAD | -2.68 M CAD |
MedMira stock margins CA58501R1029 · 932414
The MedMira margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MedMira. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MedMira.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the MedMira's sales revenue. A higher gross margin percentage indicates that the MedMira retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the MedMira's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the MedMira's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MedMira's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MedMira. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MedMira's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
MedMira Margin History
| MedMira Gross margin | MedMira Profit margin | MedMira EBIT margin | MedMira Profit margin |
|---|---|---|---|
| 2023 | 69.45 % | -449.52 % | -618.61 % |
| 2022 | 31.93 % | -152.63 % | -192.37 % |
| 2021 | 80.29 % | -8.59 % | -31.51 % |
| 2020 | 62.27 % | -141.46 % | -222.55 % |
| 2019 | 80.27 % | -245.72 % | -399.36 % |
| 2018 | 78.3 % | -312.51 % | -426.15 % |
| 2017 | 64 % | -285.43 % | -356.07 % |
| 2016 | 45.16 % | -198.46 % | -228.57 % |
| 2015 | 29.13 % | -67.65 % | -86.36 % |
| 2014 | 30.43 % | -141.11 % | -151.78 % |
| 2013 | 31.5 % | -108.5 % | -20 % |
| 2012 | 60.82 % | -222.68 % | 347.42 % |
| 2011 | 46.15 % | -204.4 % | -541.76 % |
| 2010 | 69.16 % | -214.02 % | -413.08 % |
| 2009 | 49.12 % | -220.18 % | -461.4 % |
| 2008 | 35.29 % | -210.46 % | -458.82 % |
| 2007 | 46.78 % | -207.6 % | -367.84 % |
| 2006 | 54.55 % | -262.2 % | -348.8 % |
| 2005 | 40.98 % | -167.29 % | -221.8 % |
| 2004 | 53.63 % | -139.11 % | -160.89 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 53.63 % | -139.11 % | -160.89 % |
| 2005 | 40.98 % | -167.29 % | -221.8 % |
| 2006 | 54.55 % | -262.2 % | -348.8 % |
| 2007 | 46.78 % | -207.6 % | -367.84 % |
| 2008 | 35.29 % | -210.46 % | -458.82 % |
| 2009 | 49.12 % | -220.18 % | -461.4 % |
| 2010 | 69.16 % | -214.02 % | -413.08 % |
| 2011 | 46.15 % | -204.4 % | -541.76 % |
| 2012 | 60.82 % | -222.68 % | 347.42 % |
| 2013 | 31.5 % | -108.5 % | -20 % |
| 2014 | 30.43 % | -141.11 % | -151.78 % |
| 2015 | 29.13 % | -67.65 % | -86.36 % |
| 2016 | 45.16 % | -198.46 % | -228.57 % |
| 2017 | 64 % | -285.43 % | -356.07 % |
| 2018 | 78.3 % | -312.51 % | -426.15 % |
| 2019 | 80.27 % | -245.72 % | -399.36 % |
| 2020 | 62.27 % | -141.46 % | -222.55 % |
| 2021 | 80.29 % | -8.59 % | -31.51 % |
| 2022 | 31.93 % | -152.63 % | -192.37 % |
| 2023 | 69.45 % | -449.52 % | -618.61 % |
MedMira Aktienanalyse
What does MedMira do?
MedMira Inc. is a Canadian company specializing in the development and marketing of innovative diagnostic products. It was founded in 1993 and is headquartered in Halifax, Nova Scotia. MedMira initially focused on HIV testing and developed the first rapid test kits, which proved to be highly effective and reliable. The company later expanded its product line to include diagnostics for Hepatitis and Syphilis. MedMira has become a leading provider of rapid test kits for infectious diseases, with its products being sold globally and proven to be reliable and effective in numerous studies. The company is constantly seeking new technologies and methods to expand its offerings and provide better solutions to its customers. MedMira's business model revolves around the development and marketing of diagnostic products for the medical and pharmaceutical markets. The company collaborates with leading companies and institutions in the industry to develop new products and improve existing solutions. MedMira has different divisions focused on its various diagnostic products, such as HIV, Hepatitis, and Syphilis. Each division has a dedicated team of experts focused on developing and marketing solutions tailored to meet customer needs. The company offers a wide range of products tailored to the needs of different customers and markets, including rapid test kits, ELISA kits, and other diagnostic tools. It specializes in serving specific target groups, such as pregnant women or newborns, and constantly strives to deliver better results to its customers. One example of a product from MedMira is the Reveal G4 Combo Rapid HIV-Syphilis Test, a highly accurate rapid test that detects both HIV and Syphilis infections. The test can be conducted quickly and provides results comparable to traditional tests. MedMira prides itself on being an innovative company focused on customer needs and constantly seeking new ways to improve diagnostics. It has built an excellent reputation and enjoys the trust of leading companies and institutions in the medical and pharmaceutical sectors. MedMira ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding MedMira's Profit Margins
The profit margins of MedMira represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of MedMira's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating MedMira's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
MedMira's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When MedMira’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about MedMira stock
How has the profit developed compared to last year?
The profit has increased by 46.08% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does MedMira publish its earnings?
MedMira publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of MedMira?
The profits of MedMira are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of MedMira?
You can learn more about the earnings of MedMira by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does MedMira pay?
Over the past 12 months, MedMira paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MedMira is expected to pay a dividend of 0 CAD.
What is the dividend yield of MedMira?
The current dividend yield of MedMira is .
When does MedMira pay dividends?
MedMira pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MedMira?
MedMira paid dividends every year for the past 0 years.
What is the dividend of MedMira?
For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MedMira located?
MedMira is assigned to the 'Health' sector.
Wann musste ich die Aktien von MedMira kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MedMira from 11/16/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.
When did MedMira pay the last dividend?
The last dividend was paid out on 11/16/2024.
What was the dividend of MedMira in the year 2023?
In the year 2023, MedMira distributed 0 CAD as dividends.
In which currency does MedMira pay out the dividend?
The dividends of MedMira are distributed in CAD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von MedMira
Our stock analysis for MedMira Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MedMira Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
